The role of DICKKOPF (DKK)-1 in human cancer is controversial. DKK-1 behaves as an inhibitor of the canonical Wnt/β-catenin signaling pathway acting at the plasma membrane, although several studies have proposed effects that are independent of the inhibition of β-catenin transcriptional activity, in some cases mediated by the activation of c-Jun N-terminal kinase (JNK). Recently, a proportion of DKK-1 protein has been found within the nucleus of human intestinal epithelial cells following an apical-to-basal crypt decreasing gradient, and in that of colon carcinoma cells. Moreover, we show here that in the human mammary gland DKK-1 is also present within the nucleus of many differentiated luminal epithelial cells and in that of a small proportion of myoepithelial cells. Nuclear DKK-1 binds to actively transcribed chromatin and regulates the expression of specific genes, some of which are involved in cell proliferation, survival and stemness, and in the defense against xenobiotics. This may explain the finding that while DKK-1 is downregulated more rapidly in the nucleus than in the cytosol during colon carcinoma progression, its expression remains high in a percentage of patients who do not respond to chemotherapy. Available data suggest that the accumulation of DKK-1 in the nucleus of colon carcinoma cells depends on signals from the surrounding tumor microenvironment.
Dickkopf-1 (Dkk-1) gene, "big head" in German, was originally discovered in Xenopus laevis as an embryonic head inducer and a potent antagonist of Wnt signaling [1] . In agreement, Dkk-1 -/-mice are embryonic lethal and lack head structures anterior to the mid-hindbrain boundary [2] . Human DICKKOPF1 (DKK-1) is the founding member of a family composed of four related genes, DKK-1 to 4, and a close homologue called DKK-like protein 1 (DKKL1) [3] . DKK-1 encodes a secreted glycoprotein, DKK-1, of 37 kDa with two conserved cystein-rich motifs [3] . DKK-1 binds to Wnt co-receptors LRP5 and LRP6 [4] [5] [6] [7] and inhibits the engagement of Wnt-Frizzled-LRP ternary complexes at the plasma membrane, thus avoiding Wnt/β-catenin (also called canonical) signaling. DKK-1 also binds a second class of high affinity receptors, Kremen 1 and 2 [8] . Kremen proteins form ternary complexes with DKK-1 and LRPs, which results in endocytosis of the complex and therefore removal of LRPs from the plasma membrane and inhibition of Wnt/β-catenin signaling [8] . Kremen proteins are not universally required for DKK-1 function, as revealed in mice deficient in kremen genes [9] and as shown by the capacity of DKK-1 to modulate canonical signaling via direct blocking of Wnt-LRP interactions [6] . Interestingly, DKK-1 not only encodes a Wnt antagonist but is also a β-catenin/TCF target gene [10] [11] [12] , and thus acts as a negative feedback regulator of the pathway.
RESEARCH HIGHLIGHT
Wnt proteins perform a vast number of actions in organisms, both during development and in adult life [13] . As a Wnt inhibitor, DKK-1 also affects numerous developmental processes such as body axis patterning or somitogenesis, as well as bone formation in the adult organism [14] . Remarkably, several authors have reported Wnt-independent actions of DKK-1. Expression of DKK-1 in β-catenin-deficient mesothelioma cell lines suppresses cell growth and induces apoptosis, apparently through activation of the c-Jun N-terminal kinase (JNK) pathway [15] . Likewise, DKK-1 induces apoptosis in human placental choriocarcinoma cells independently of Wnt/β-catenin signaling and requires JNK activity [16] . JNK activation is also responsible for neurite formation in Ewing's sarcoma cells treated with DKK-1 [17] . Moreover, ectopic expression of DKK-1 in HeLa cervical carcinoma cell line results in decreased growth in soft agar and tumor formation in athymic mice independently of β-catenin/TCF transcriptional activity [18] . In breast cancer cell lines DKK-1 also has β-catenin-independent tumor suppressor effects which correlate with increased activity of Ca 2+ /calmodulin-dependent protein kinase II pathway [19] . In line with these studies, we have reported Wnt-independent tumor suppressor effects of DKK-1 in colon carcinoma cells [20] . However, recent findings indicate that these cells can respond to exogenous and autocrine Wnt factors despite having mutations that stabilize β-catenin and thus the canonical pathway is activated intracellularly [21] . It is thus necessary to re-examine whether those effects are completely independent of canonical Wnt signaling. In summary, although accumulated evidence suggests that DKK-1 has functions other than inhibiting Wnt/β-catenin signaling at the plasma membrane, this issue remains open at least in some systems.
The role of DKK-1 in human cancer is controversial. It has been shown to be both upregulated and downregulated depending on the type of tumor. The strongest evidence of DKK-1 overexpression comes from myeloma and hepatocellular carcinoma (HCC). Multiple myeloma is characterized by the appearance of osteolytic bone disease, which is due to augmented bone resorption by osteoclasts and reduced bone formation by osteoblasts. The levels of DKK-1 in serum of patients with multiple myeloma are higher than those in healthy controls and there is a good correlation with osteolytic bone disease [22] . Thus, there is mounting evidence that DKK-1 might be a good target for immunotherapy in myeloma patients [23] , and a recent study has demonstrated that active vaccination with DKK-1 induces protective antitumor immunity against multiple myeloma in rodents [24] . DKK-1 is also a diagnostic and prognostic serum marker in HCC [25] [26] [27] [28] and it promotes invasion and metastasis of HCC cells [27] . It has recently been shown that both DKK-1 and osteopontin enhance the diagnostic value of alpha-fetoprotein, the most widely used biomarker for HCC [29] . Other tumor types in which enhanced expression of DKK-1 has been reported include prostate, breast, gastric, ovarian, glioma, esophagic or pancreatic cancer [30] [31] [32] [33] [34] [35] [36] . Notably, high expression of DKK-1 frequently correlates with increased invasive and metastatic capacity of a variety of tumors [36] [37] [38] [39] , which suggests that DKK-1 might be a metastasis promoter for some neoplasias. Moreover, in some cases DKK-1 levels fluctuate during cancer progression. Feldmann and colleagues showed that DKK-1 increases early in melanoma but then decreases in later tumor stages, which was interpreted as a sign of loss of tumor control [40] . Likewise, Hall and colleagues reported an early increase of DKK-1 expression levels in prostate cancer, which then diminished throughout progression from primary tumor to metastasis [41] . DKK-1 is downregulated in a number of tumors, of which colon cancer is the most paradigmatic. We and others have reported reduced expression of DKK-1 in colon cancer [11, 42] that in a proportion of cases is associated with promoter hypermethylation [20, 43, 44] . This was an unexpected finding because as a β-catenin/TCF target DKK-1 gene was predicted to be upregulated in a malignancy characterized by a constitutively hyperactivated Wnt/β-catenin pathway. Supporting these data, analysis of DKK-1 expression in human colon tumors demonstrated an inverse correlation with tumor grade, presence of metastasis, and recurrence [45] . Moreover, downregulation of DKK-1 expression is concomitant with reduced epithelial-to-mesenchymal transition (EMT) phenotype [45] , and with reduced angiogenesis and VEGF expression [42] . The complex behavior of DKK-1 as a tumor suppressor or metastasis promoter may rely on the diverse and sometimes opposite actions of Wnt/β-catenin signaling in different tissues, together with other Wnt-independent effects that may add to the array of DKK-1 actions.
The recent demonstration by our group that DKK-1 is present within the nucleus of human enterocytes and colon cancer cells may help us to understand its biological functions [46] . Besides its expected localization in the cytoplasm and plasma membrane, DKK-1 protein has been found in the nucleus in a high proportion of differentiated cells (i.e. enterocytes and mucosecretory goblet cells) located in the upper half of colon and small intestine crypts. In the latter, nuclear DKK-1 expression was also detected in enteroendocrine cells at the bottom of the crypts. In contrast, stem cells at the bottom of the crypts and proliferating undifferentiated cells in the basal epithelia contained cytoplasmic but not nuclear DKK-1 in both colon and small intestine [46] . Moreover, new studies on DKK-1 expression in the human mammary gland show that nuclear DKK-1 is present in 83.8% of differentiated cytokeratin (CK)7-positive luminal epithelial cells but almost absent (2.9%) in CK5-positive basal and myoepithelial cells (P < 0.001) (Figure 1 ). Stromal cells in both intestine and mammary gland showed very low DKK-1 expression. This association between nuclear presence and differentiated cell stage suggests that nuclear DKK-1 could be involved in modulating the switch between proliferation and differentiation in the intestine and mammary gland epithelia. Nuclear DKK-1 binds to actively transcribed chromatin and regulates the expression of many genes, some of which are involved in cell proliferation, survival and stemness, and in xenobiotic defense [46] . In colon cancer, downregulation of nuclear DKK-1 at early steps of cancer progression is faster than that of DKK-1 outside the nucleus [46] . This favors the idea that DKK-1 within this compartment contributes, through regulation of its target genes, to the antiproliferative and global tumor suppressive action that is classically attributed to inhibition of Wnt signaling at the plasma membrane. Paradoxically, despite its protective effects in normal tissue and at early stages of progression, we have shown that a proportion of colorectal carcinomas retain nuclear DKK-1 expression and this is associated with a resistance to chemotherapy. Upregulation of genes such as aldehyde dehydrogenase 1A1 (ALDH1A1) and Ral-binding protein 1-associated Eps domain-containing 2 (REPS2), which are involved in detoxification of chemotherapeutic agents, most probably explains this resistance to chemotherapy and lower survival rates of patients whose tumors express nuclear DKK-1 [46] . The presence of a proportion of DKK-1 protein in the nucleus regulating gene expression adds complexity to the proposed β-catenin-dependent and -independent mechanisms of action. It is thus necessary to re-evaluate previous studies based on the analysis of DKK-1 RNA or total cellular protein levels. Techniques to measure the subcellular localization of proteins such as immunohistochemistry, immunofluorescence or Western blotting of purified cellular fractions are required to yield an appropriate pattern of DKK-1 expression.
Finally, both the existence of a gradient in vivo in the level of nuclear DKK-1 along the intestinal crypts and of a higher amount of nuclear DKK-1 in tumor cells of chemoresistant colorectal cancer patients than those in cultured carcinoma cells [46] suggest that nuclear accumulation of this protein is a non-cell-autonomous effect but, in contrast, is regulated by external signals probably coming from the stroma in normal tissue and from the tumor microenvironment in cancer patients (Figure 2 ). Given the role that nuclear DKK-1 appears to have for the response to chemotherapy in colon cancer [46] , identification of the nature and origin of such proposed signals is of utmost importance. 
